{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"MK-1022-016","nct_id":"NCT07060807","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=mk-1022-016-nct07060807. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive patritumab deruxtecan via intravenous (IV) infusion every 3 weeks (Q3W) for approximately 13 months.","label":"Patritumab Deruxtecan","type":"EXPERIMENTAL"},{"description":"Participants receive treatment of physician's choice (TPC) for up to 13 months. The TPC may be any of the following options: Paclitaxel (80 mg/m\\^2) on Days 1, 8, 15, and 22 of each 4-week cycle; Paclitaxel (90 mg/m\\^2) on Days 1, 8, and 15 of each 4-week cycle; Nab-paclitaxel (100 mg/m\\^2) on Days 1, 8, and 15 of each 4-week cycle; Capecitabine (1000 mg/m\\^2) bid on Days 1 to 14 of each 3-week cycle; Pegylated liposomal doxorubicin (50 mg/m\\^2) on Day 1 of each 4-week cycle; or trastuzumab deruxtecan (T-DXd) (5.4 mg/kg) Q3W.","label":"Treatment of Physician's Choice","type":"ACTIVE_COMPARATOR"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2033-07-14","type":"ESTIMATED"},"conditions":["Breast Neoplasms"],"enrollment":{"count":1000,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Patritumab deruxtecan","otherNames":["MK-1022","HER3-DXd","U3-1402"],"type":"BIOLOGICAL"},{"name":"Paclitaxel","otherNames":["TAXOL®","ONXAL®"],"type":"DRUG"},{"name":"Nab-paclitaxel","otherNames":["Abraxane®"],"type":"DRUG"},{"name":"Capecitabine","otherNames":["XELODA®"],"type":"DRUG"},{"name":"Pegylated liposomal doxorubicin","otherNames":["Doxil®"],"type":"DRUG"},{"name":"Trastuzumab deruxtecan","otherNames":["T-DXd","Enhertu®"],"type":"BIOLOGICAL"},{"name":"Rescue Medication","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-23","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04).","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2033-07-14","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS)","timeFrame":"Up to approximately 45 months"},{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 85 months"}],"references":[],"start_date":{"date":"2025-07-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","url":"https://clinicaltrials.gov/study/NCT07060807"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/mk-1022-016-nct07060807"}